Loading...
An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials
Dose-finding in cancer clinical trials has been dominated by algorithmic designs on the principle that the highest tolerable dose is also the most effective dose. This assumption no longer applies to the biologic treatments that are characterized by different toxicity and/or efficacy profiles to the...
Na minha lista:
| Udgivet i: | Stat Biopharm Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6277027/ https://ncbi.nlm.nih.gov/pubmed/30524665 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19466315.2018.1462727 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|